US Bancorp’s Sutro Biopharma STRO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-5
Closed -$183 4263
2024
Q3
$183 Sell
5
-1,195
-100% -$46.8K ﹤0.01% 4018
2024
Q2
$35.2K Sell
1,200
-500
-29% -$19.8K ﹤0.01% 2836
2024
Q1
$96K Buy
+1,700
New +$75.1K ﹤0.01% 2386
2022
Q2
Sell
-74
Closed -$6K 4223
2022
Q1
$6K Buy
74
+53
+252% +$5.04K ﹤0.01% 3564
2021
Q4
$3K Sell
21
-62
-75% -$11.1K ﹤0.01% 3830
2021
Q3
$16K Buy
+83
New +$15.8K ﹤0.01% 3244

Other funds holding STRO

US Bancorp's STRO Position: Q4 2024 in Review

US Bancorp sold out of Sutro Biopharma (STRO) in Q4 2024, closing a stake of 5 shares — an estimated $183 sold.

US Bancorp first reported a position in STRO in Q3 2021 and held it in 6 quarters. The position peaked at $96K in Q1 2024. 122 funds tracked by Wall St. Rank hold STRO as of Q4 2024.

  • US Bancorp reported no remaining Sutro Biopharma position as of Q4 2024 after selling out during the quarter.
  • US Bancorp sold 5 Sutro Biopharma shares in Q4 2024, an estimated $183.
  • US Bancorp first reported a position in Sutro Biopharma in Q3 2021 and held it in 6 quarters.
  • US Bancorp's Sutro Biopharma position peaked at $96K in Q1 2024.
  • 122 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2024.

Based on US Bancorp's 13F filing for Q4 2024, filed 5 Feb 2025.